Oramed Pharmaceuticals Inc.
ORMP
$2.12
-$0.05-2.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 196.74% | -- | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 196.74% | -- | -100.00% | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -98.07% | -- | -100.00% | -100.00% |
| SG&A Expenses | -10.37% | -17.62% | -20.66% | -29.84% | -30.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.81% | 14.95% | -25.30% | -44.77% | -56.58% |
| Operating Income | -6.26% | -5.89% | 18.95% | 39.61% | 52.22% |
| Income Before Tax | -199.25% | -339.54% | -412.89% | 142.25% | 207.55% |
| Income Tax Expenses | 22.83% | -- | -- | -- | 1,534.00% |
| Earnings from Continuing Operations | -216.74% | -376.35% | -475.45% | 125.92% | 199.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -45.54% | -81.61% | -90.16% | -87.63% | -84.47% |
| Net Income | -215.82% | -370.07% | -444.98% | 127.30% | 203.32% |
| EBIT | -6.26% | -5.89% | 18.95% | 39.61% | 52.22% |
| EBITDA | -6.96% | -6.34% | 19.17% | 40.16% | 52.81% |
| EPS Basic | -216.68% | -368.44% | -446.70% | 127.23% | 200.02% |
| Normalized Basic EPS | -145.32% | -180.17% | -132.73% | -59.68% | 47.73% |
| EPS Diluted | -224.03% | -382.35% | -472.91% | 124.82% | 197.69% |
| Normalized Diluted EPS | -148.48% | -183.16% | -133.82% | -58.79% | 48.45% |
| Average Basic Shares Outstanding | 1.09% | 1.06% | 1.32% | 1.92% | 2.50% |
| Average Diluted Shares Outstanding | 0.17% | 0.38% | 1.53% | 3.40% | 3.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |